Bayer Aktiengesellschaft (BAYRY) Set to Post Earnings on Tuesday

Key Points

• Bayer is expected to report earnings before the market opens Tuesday, November 3. Analysts forecast quarterly EPS of $0.13 and revenue of $11.25 billion, with full-year 2026 EPS guidance of $1.20–$1.35.
• In its previous quarter, Bayer earned $0.29 per share, beating estimates of $0.23, while revenue of $12.53 billion exceeded expectations of $12.31 billion.
• Shares opened at $12.69 and have traded between $7.48 and $15.23 over the past year. Analysts maintain a consensus Buy rating, supported by recent upgrades from Zacks Research and Deutsche Bank.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) is anticipated to post its results before the market opens on Tuesday, November 3rd. Analysts expect Bayer Aktiengesellschaft to announce earnings of $0.13 per share and revenue of $11.25 billion for the quarter. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.06. The firm had revenue of $12.53 billion during the quarter, compared to analyst estimates of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. On average, analysts expect Bayer Aktiengesellschaft to post $1.27 EPS for the current fiscal year and $1.32 EPS for the next fiscal year.

Bayer Aktiengesellschaft Stock Performance

Shares of OTCMKTS:BAYRY opened at $12.69 on Tuesday. The firm's 50-day moving average is $13.52 and its 200 day moving average is $12.49. Bayer Aktiengesellschaft has a 12 month low of $7.48 and a 12 month high of $15.23. The company has a current ratio of 1.04, a quick ratio of 0.67 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $49.87 billion, a price-to-earnings ratio of -24.88, a PEG ratio of 1.86 and a beta of 0.57.

Wall Street Analysts Forecast Growth

BAYRY has been the topic of several recent research reports. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Thursday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of "Buy".

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.

Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women's health, oncology, hematology and specialty therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.